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Summary
Alzheimer’s disease (AD) is a multi-causal neurodegenerative dis-
order and the most common form of dementia in the elderly. Although
extensively investigated, the exact underlying molecular and cellular
mechanisms of AD remain to be fully elucidated. Amongst other
factors, AD may be associated with increased oxidative stress and
chronic inflammation. Although dietary antioxidants, in particular
vitamin E, have been related to a reduction of AD risk, data from
clinical studies are still contradictory. Aside from increasing age, one
key risk factor for sporadic AD is the apolipoprotein E4 genotype. As
major component of lipoproteins the apolipoprotein E (apoE) is of
crucial importance in the distribution of cholesterol and lipids within
the brain and thus, involved in neuronal membrane repair mechanisms.
However, apoE4 has been associated with several altered cellular
features including an impaired neuronal repair function and a higher
neuronal vulnerability towards oxidative insults leading to an increased
AD risk. In this context, the role of antioxidant supplementation as a
primary prevention strategy for subjects at high risk including carriers
of the apoε4 allele, is discussed.
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative
disorder of the elderly and the most frequent cause of dementia during
aging in Western countries. Every year 250,000 new AD patients are
confirmed in Germany. Prevalence of AD increases with age from
0.4% at <65 years of age to 10% at >65 years of age. Only a small
percentage of the AD cases exhibits a familial trait with an early di-
sease onset (<65 years of age), more than 90% of the patients develop
a sporadic form (LAWS et al., 2003). The progressive disorder is
characterised by massive neuronal loss in specific brain regions
important for cognition and memory such as the hippocampus and
parts of the cortex. Histopathological hallmarks of the AD are extra-
cellular depositions containing amyloid β (Aβ) peptides and intra-
cellular neurofibrillary tangles (NFT) of the hyperphosphorylated tau
protein. A profile of cellular abnormalities occurs in AD including
oxidative stress, mitochondrial dysfunction and impaired regulation
of cellular calcium homeostasis (MATTSON, 2000). Furthermore, AD
brains exhibit profound loss of synapses, microglial activation and
inflammatory processes (PRATICO and TROJANOWSKI, 2000; SELKOE,
2002).
The amyloid precursor protein (APP) is considered to play a central
role in the AD pathology corroborated by the fact that autosomal domi-
nant inherited forms of the Alzheimer’s dementia are mainly caused
by mutations of three genes including APP and presenilines-1/2
(PS-1 and PS-2), which are involved in APP processing. The trans-
membrane glycoprotein APP comprises a large extracellular C-terminal
domain, a membrane-spanning domain and an intracellular N-terminus
(GRALLE and FERREIRA, 2007). Major consequences for AD pathology
arise from the amyloid β sequence, which is located partly in the extra-
cellular and the trans-membrane domain of APP.
Proteolytic activity of enzymes called β- and γ-secretase (see Fig. 1)
contributes to the release of the toxic Aβ fragment whereas α-secretase
cleavage hinders Aβ production (HAASS et al., 1992). The secreted
Aβ peptides are hydrophobic and form insoluble fibrils that aggregate
and accumulate in the extracellular matrix as amyloid plaques. The
main Aβ species consist of 40 to 42 amino acids with the 42 amino
acid form being deposited first (IWATSUBO et al., 1994).
Amyloid plaques are supposed to produce reactive oxygen species
and thereby injuring surrounding neuronal membranes and initiating
neurite degeneration (HENSLEY et al., 1995). The association of amyloid
plaques with astrocytes and activated microglia induce cytokine pro-
duction and inflammatory processes (SELKOE, 1999). Thus, occurrence
of amyloid plaques is accompanied by chronic inflammatory burden
which may in turn contribute to neuronal degeneration.
Apolipoprotein E
Apolipoprotein E (apoE) is one of the different classes of apolipo-
proteins in the body and is a main regulator of cholesterol transport.
Fig. 1: Scheme of the alternative cleavage pathways of the transmembrane protein amyloid precursor protein (APP) by either α-secretase (non-amyloidogenic)
or β-secretase (amyloidogenic).
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Several tissues synthesize apoE and of these, the liver and the brain
are major sites of apoE expression. Moreover, besides apoJ, apoE is
the major apolipoprotein in the brain suggesting its primary role in
the central nervous system. ApoE is considered to distribute cholesterol
from astrocytes to neurons based on the fact that astrocytes are the
main source of apoE and cholesterol in the brain whereas neurons
express receptors to endocytose apoE and cholesterol from lipoproteins
(LAWS et al., 2003). Nevertheless, a part of activated microglia and
many neurons have been shown to express apoE in response to injury
(XU et al., 2006) suggesting that apoE may play a pivotal role in
inflammatory and repair processes in the brain.
The apoE gene is subjected to numerous single nucleotide poly-
morphisms and the common polymorphism gives rise to three apoE
genotypes, apoE2, apoE3 and apoE4. From these arise three homo-
zygous (E2/2, E3/3, E4/4) and three heterozygous (E2/3, E3/4, E2/4)
phenotypes with different distribution throughout population and
different susceptibility towards AD progression. ApoE allelic distri-
bution varies worldwide, but the apoε3 allele is always the most
abundant. In a selected German population allelic distribution was
reported to be 8.1% for ε2, 78.2% for ε3 and 13.6% for ε4 (SINGH
et al., 2006).
Tab. 1: ApoE genotype frequency in the general population (USA) and in
AD-patients (according to RABER et al., 2004).
apoE genotype population AD
ε2/ε2 1 % 0.1 %
ε2/ε3 12 % 4 %
ε3/ε3 60 % 35 %
ε3/ε4 21 % 42 %
ε4/ε4 2 % 16 %
The frequency of individual phenotypes is shifted in AD patients
compared to general population, whereby frequency of the E3/4
phenotype increases to 42% (from 21% in general) and of the E4/4
genotype to 16% (from 2% in general) (RABER et al., 2004). Thus,
apoε4 allelic frequency has been reported to increase from ap-
proximately 14% in the control population to around 40% in the AD
population (POIRIER et al., 1993) and age of disease onset is decreased
in association with apoE4 (LOCKE et al., 1995). In addition, there is
also an apparent gene dosage effect according to the number of the
apoε4 alleles. Thus, the risk for AD rises from 20% when no apoε4
allele is present to 90% when two copies of the apoε4 allele are present
in 42 families with late onset AD (CORDER et al., 1993). On the other
side, it has been shown that the apoε2 allele is associated with a delayed
age of onset, and in addition, the ε2 allele is under-represented in
AD compared to control population (POIRIER et al., 1993). From these
findings it was proposed that the ε4 allele increases AD risk whereas
the ε2 allele of the apoE gene has a protective effect against the de-
velopment of AD.
The apoE protein contains 299 amino acids and has a mass of ap-
proximately 34 kDa. The primary structure of the three common iso-
forms varies at two sites of the protein: 112 and 158. ApoE2 has two
cystein and apoE4 two arginine residues at these positions whereas
apoE3 has a cystein at position 112 and an arginine residue at position
158. In apoE2, cystein at position 158 results in less effective binding
to the LDL receptor family and type III hyperlipoproteinaemia, a lipid
disorder characterised by increased plasma level of triglycerides and
cholesterol (MAHLEY et al., 2006). In apoE4, the arginine residue at
position 112 causes a domain interaction which is associated with
reduced protein stability and different lipoprotein preferences com-
pared to apoE3 and E2. Due to the conformational difference, apoE4
favours to bind to large lower-density lipoproteins, VLDL and LDL,
whereas apoE3 and E2 prefer smaller, cholesterol-rich particles, HDL
(HATTERS et al., 2006). This contributes to differences in lipoprotein
metabolism and thus, total cholesterol and LDL cholesterol levels are
elevated in apoε4 carriers. Due to higher remnant catabolism, the LDL
receptors were supposed to be down regulated thereby increasing LDL
level in apoε4 carriers (MAHLEY and RALL, 2000). On that account,
apoE4 was associated with an increased risk for cardiovascular disease
but more evident seems to be the involvement of apoE4 in neuro-
degenerative processes.
ApoE and neurodegeneration
Several cellular features in the brain seem to be altered in the apoE4
as compared to the apoE3 genotype (see Fig. 2). Due to the limited
ability of neurons to regenerate, the maintenance of synaptic function
is of crucial importance. Specific brain areas such as the hippocampus
are able to induce formation of presynaptic extensions, and this process
of compensatory synaptogenesis is accompanied by increased apoE
expression. Thus, synaptic repair is a key function of apoE and it has
been reported to be impaired in apoε4 carriers (POIRIER, 1994).
Fig. 2: Role of apoE3 and apoE4 in neuronal functions.
synaptic end
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In the cerebrospinal fluid cholesterol and lipids are transported in small
high-density lipoprotein-like particles (LADU et al., 2000) and thereby
can be delivered to sites of injury for repair of cells and synaptic ends.
As the preference of apoE4 is lower for high-density than for low-
density lipoproteins and apoE4 containing lipoprotein remnant
catabolism is increased in relation to apoE3, insufficient neuronal
uptake and intracellular cholesterol transfer may be likely to account
for impaired neuronal membrane repair in the apoE4 genotype. In
this regard apoE4 compared to apoE3 has been shown to inhibit neurite
outgrowth (BELLOSTA et al., 1995; HOLTZMAN et al., 1995). Further
information on the impact of the apoE genotype are gained from trans-
genic mouse models, where apoE4 has been reported to be associated
with a smaller number of presynaptic ends, a higher plaque density
and increased degree of tau phosphorylation. Moreover, memory,
cognitive performance and synaptic plasticity are impaired in the
apoE4 genotype (RABER et al., 2000; MAHLEY et al., 2006).
As mentioned above, the production and accumulation of amyloid β
are major cornerstones in the pathogenesis of AD. In this context,
decreased clearance and increased deposition of Aβ in the apoE4
genotype contribute to the detrimental impact of apoE4 compared to
apoE3 in AD progression. Furthermore, the apoE4 isoform has been
shown to enhance Aβ production in vitro and this effect has been
attributed to mediation through the domain interaction caused by the
arginine residue at position 112 (YE et al., 2005). In transgenic mice
with human apoE3 or apoE4 replacing murine apoE in the mouse
genome it has been demonstrated that alpha-secretase expression is
decreased in apoE4 compared to apoE3 mice (Fig. 3) suggesting a
shift from the non-amyloidogenic to the amyloidogenic cleavage
pathway in relation to the apoE genotype (HUEBBE et al., 2007b).
are assumed to be key mechanisms for the Aβ-independent neuro-
pathology involving apoE4 (MAHLEY et al., 2006).
While many aspects of the apoE4-AD association have been discussed
lately, one of the first putative mechanisms was supposed to be the
apoE allele-specific antioxidant activity. The apoE4 isoform has been
shown to protect neuronal cells in vitro against oxidative insults to a
lesser extent than apoE3 (Fig. 4), whereas apoE2 exhibited most pro-
tection (MIYATA and SMITH, 1996; HUEBBE et al., 2007a). Moreover,
in stably transfected macrophages the apoE4 relative to the apoE3
genotype increases the production of superoxides, a prominent member
of reactive oxygen species (JOFRE-MONSENY et al., 2007a).
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Fig. 3: Relative mRNA and activity level of non-amyloidogenic α-secretase
in the brain of apoE3 and apoE4 transgenic mice. * indicates a sig-
nificant (p<0.05) apoE4 genotype dependent effect compared to apoE3.
(According to HUEBBE et al., 2007b).
Besides all, cognitive impairment and functional brain abnormali-
ties related to apoE4 have been found also in non-demented subjects
(BAXTER et al., 2003; CASELLI et al., 2004; REIMAN et al., 2004) sug-
gesting a global effect of the apoE genotype on brain function prior to
the onset of AD symptoms. Thus, mitochondrial dysfunction associated
with AD has been observed to be more pronounced in apoE4 subjects
(GIBSON et al., 2000) and disruption of mitochondrial regulation of
energy and glucose metabolism in neurons has been shown in both
healthy and demented apoε4 carriers (SMALL et al., 1995). Due to the
lower apoE4 protein stability, increased formation of apoE4 fragments
has been supposed to interact with the cytoskeletal components and
to induce formation of neurofibrillary tangles (HUANG et al., 2001).
Mitochondrial and cytoskeletal alterations caused by apoE4 fragments
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Fig. 4: Effect of apoE3 and apoE4 conditioned media on neuronal cell viability
following hydrogen peroxide challenge. * indicates a significant dif-
ference between apoE3- and apoE4-cultured cells. (According to
HUEBBE et al., 2007a).
Oxidative stress is linked to inflammatory processes and increased
innate immune activity in the brain. Importantly, activation of immune
response including production of pro-inflammatory cytokines is higher
in apoE4-macrophages (JOFRE-MONSENY et al., 2007b) and apoE4-
microglia (MAEZAWA et al., 2006a) compared to the apoE3 genotype.
Neurotoxicity mediated by activated microglia, cells mediating the
innate immune response in the brain similar to macrophages, is more
pronounced in apoE4 than apoE3 transgenic mice (MAEZAWA et al.,
2006b). Moreover, production of anti-inflammatory mediators such
as interleukin-10 is lower in the apoE4 compared to the apoE3 geno-
type (JOFRE-MONSENY et al., 2007b).
Vitamin E
As alterations in the oxidant/antioxidant balance are considered a
primary feature of AD the lower antioxidant activity of apoE4 may be
associated with a higher requirement of dietary antioxidants in apoε4
carriers (DREON and PEROUTKAL, 2001). In this regard, vitamin E
is of particular interest since it is the major lipid soluble antioxidant
in the human body. Vitamin E is the most effective chain-breaking
antioxidant in biological membranes, where it contributes to membrane
stabilisation and protection of functional molecules and cellular
structures against damage from free radicals (MEYDANI, 1995).
Furthermore, vitamin E is especially suitable to improve antioxidant
status in the brain by easily crossing the blood-brain-barrier. Vitamin
E is a generic term used to describe at least four forms of (α-, γ-, β-,
δ-) tocopherols and tocotrienols (Fig. 5), which exhibit the biological
functions in varying activity (RIMBACH et al., 2002). Compared to the
other tocopherols α-tocopherol is preferentially incorporated into lipo-
proteins and secreted into the plasma facilitated by the α-tocopherol
transfer protein (α-TTP) (BRIGELIUS-FLOHE and TRABER, 1999).
Furthermore, hepatic degradation of vitamin E to the corresponding
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Evidence of a role for vitamin E in protecting against the onset of AD
and its progression in humans is based largely on epidemiological
data, where lower plasma, brain and cerebrospinal fluid (CSF) vitamin
E levels were detected in AD patients relative to matched control groups
(TOHGI et al., 1994; GRUNDMAN and DELANEY, 2002; RINALDI et al.,
2003). Morris and co-workers observed a lower rate of development
of AD in individuals who regularly consumed vitamin E supplements
relative to the non-supplement users in a 4 year prospective study of
non-AD elderly participants at baseline (MORRIS et al., 2002). Ad-
ditionally, in vitro studies support a potential role for vitamin E in AD
prevention (HALKS-MILLER et al., 1986; BEHL et al., 1992; LUCHSINGER
and MAYEUX, 2004; HUEBBE et al., 2007a).  However, only one clinical
trial in subjects with established AD suggested that a high dose vitamin
E supplementation (2000 IU/d) delayed disease progression (SANO
et al., 1997). On the other hand, there have been several contradictory
clinical studies showing no benefit from vitamin E supplementation
(1000-2000 IU/d) in AD patients (KLATTE et al., 2003; FILLENBAUM
et al., 2005; PETERSEN et al., 2005).
Albeit the discussion whether high dietary vitamin E intake is beneficial
or not, the molecular mechanisms of potential protective effects remain
poorly understood. Whereas beneficial effects of vitamin E may be
partly attributable to its antioxidant activity, thereby reducing oxidative
modification within the neuronal cell, it is likely that vitamin E also
mediates its biological role through non-antioxidant molecular targets
in the brain tissue. The first observations of a cell signalling role for
vitamin E were made in 1991 by Azzi and co-workers (BOSCOBOINIK
et al., 1991) who demonstrated that vitamin E inhibited protein kinase
C activity and cell proliferation in cultured cells.
Advances in microarray technology have allowed us to investigate
genes differentially expressed in various tissues including liver
(BARELLA et al., 2004; RIMBACH et al., 2004), testes (ROTA et al., 2004),
prostate (SILER et al., 2004), cortex (GOHIL et al., 2003), hippocampus
(ROTA et al., 2005) and total brain homogenates (ROY et al., 2002) in
response to vitamin E deficiency thereby offering the possibility of
more insight into the molecular functions of vitamin E. In this context,
several AD related genes have been identified to be regulated by dietary
alpha-tocopherol. In particular, vitamin E strongly affected a number
of genes that were associated with hormone activities and hormone
metabolism, nerve growth factor, apoptosis, dopaminergic neurotrans-
mission, and clearance of amyloid beta (Aβ) and advanced glycated
end products (AGE) (ROTA et al., 2005). These data demonstrate that
vitamin E in vivo may affect the expression of an array of genes en-
coding for proteins directly or indirectly involved in the prevention of
AD pathogenesis.
water-soluble hydroxychromans is shifted to favour of non-α-vitamin
E forms (SONTAG and PARKER, 2002). However, in vitro, in contrast to
α-tocopherol, γ-tocopherol is suggested to act as a trap for membrane-
soluble electrophilic reactive nitrogen species (CHRISTEN et al., 1997).
Furthermore, tocotrienols are supposed to posses neuroprotective
properties at a much lower concentration than α-tocopherol and may
exhibit cholesterol lowering properties in vitro and in vivo (PACKER
et al., 2001).
A number of cell culture and animal studies using models of neuro-
degeneration have suggested a protective role for vitamin E in the
reduction of oxidative damage, glycation and amyloid beta toxicity
(USUKI et al., 2001). The symptoms of vitamin E deficiency in alpha-
tocopherol transfer protein (α-TTP) knock-out mice include neuro-
logical impairment, ataxia and dysfunctional reflexes accompanied
by increased oxidative damage in the brain tissue. Vitamin E sup-
plementation has been shown to decrease oxidative damage and prevent
neurodegeneration in TTP knock out mice (YOKOTA et al., 2001). In
our own studies pre-incubation of neuronal cells with different vitamin
E forms exhibited significant protection against peroxide-induced cell
death (Fig. 6).
Fig. 5: Molecular structure of vitamin E stereoisomers.
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Fig. 6: Protective effects of a pre-incubation of neuronal cells with different
vitamin E forms against peroxide induced cell death (tert butyl
hydroperoxide, tBHP). *indicates significant (p<0.001) effects of a
vitamin E pre-treatment on neuronal viability (according to HUEBBE
et al., 2007a).
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ApoE genotype and dietary vitamin E
As the complexity of pathological cellular features contributes to the
lack of therapeutic success and the prevention of AD is being more
and more of primary importance the identification of subjects at high
AD risk is required most. Accordingly, the apoE genotype as well as
lifestyle and dietary factors have been discussed as determinants of
AD disease risk. It is of considerable interest if one’s risk for AD may
be reduced by preventive strategies similar to those that reduce the
risk of cardiovascular disease (MATTSON, 2004). Interestingly, it has
been shown that the apoE4 genotype enhances adverse effects of
cigarette smoking on cardiovascular disease risk (HUMPHRIES et al.,
2001) and that apoε4 carriers benefit to a certain extent from dietary
antioxidant supplementation as far as inflammatory gene expression
is concerned (MAJEWICZ et al., 2005).
Recent studies suggest that vitamin E metabolism is different in
apoE4 to non-apoE4 subjects (PROTEGGENTE et al., 2006) indicating
a lower peripheral α-tocopherol concentration in  apoε4 carriers due
to increased retention of vitamin E in plasma (LODGE et al., 2004).
Furthermore, in our own studies lower α-tocopherol concentrations
were evident in tissues of apoE4 compared to apoE3 mice with the
highest difference in the lung, whereas plasma α-tocopherol tended
to be higher in the apoE4 as compared to the apoE3 genotype. We
hypothesize that the vitamin E uptake from circulating low-density
and high-density lipoproteins via lipoprotein receptors is affected by
the apoE genotype (JOFRE-MONSENY, 2007). Mas and co-workers
(2006) proposed that the apoE4 genotype is associated with a functional
vitamin E deficiency in the brain due to an impaired delivery of this
antioxidant to the neuronal tissue (MAS et al., 2006).
In consequence, the benefit of a dietary vitamin E supplementation
may partly depend on the apoE genotype. In a prospective study, Morris
and co-workers observed a positive association of vitamin E and the
lower risk of AD only among individuals who were non apoε4 carriers
(MORRIS et al., 2002). On that account, supplementation of apoε4
carriers with vitamin E as suggested by DREON and PEROUTKAL (2001)
to reduce the risk for AD is still an open issue. Furthermore, sys-
tematic investigations on the peripheral vitamin E metabolism in
relation to the apoE genotype are needed.
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